Skip to main content
. Author manuscript; available in PMC: 2019 May 17.
Published in final edited form as: Prostate. 2018 Jan 25;78(5):401–407. doi: 10.1002/pros.23484

TABLE 2.

Comparison of the prevalenve of deleterious germline mutations in this study compared to the Pritchard et al9 study

Gene This study (N = 150) Pritchard et al9 NEJM (N = 692)
BRCA2 9/150 (6.0%) 37/692 (5.3%)
ATM 3/150 (2.0%) 11/692 (1.6%)
CHEK2 3/150 (2.0%) 10/534 (1.9%)
BRCA1 2/150 (1.3%) 6/692 (0.9%)
PALB2 1/150 (0.7%) 3/692 (0.4%)
NBN 1/150 (0.7%) 2/692 (0.3%)
MSH6 1/150 (0.7%) 1/692 (0.1%)
CDH1 1/150 (0.7%) Not analyzed
“VUS” 30/150 (20.0%) Not reported